C4 Therapeutics, Inc.CCCCEarnings & Financial Report
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.
CCCC Q4 FY2025 Key Financial Metrics
Revenue
$11.0M
Gross Profit
N/A
Operating Profit
$-23.1M
Net Profit
$-20.5M
Gross Margin
N/A
Operating Margin
-210.1%
Net Margin
-186.0%
YoY Growth
112.8%
EPS
$-0.09
C4 Therapeutics, Inc. Q4 FY2025 Financial Summary
C4 Therapeutics, Inc. reported revenue of $11.0M (up 112.8% YoY) for Q4 FY2025, with a net profit of $-20.5M (up 40.7% YoY) (-186.0% margin).
Key Financial Metrics
| Total Revenue | $11.0M |
|---|---|
| Net Profit | $-20.5M |
| Gross Margin | N/A |
| Operating Margin | -210.1% |
| Report Period | Q4 FY2025 |
C4 Therapeutics, Inc. Annual Revenue by Year
C4 Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $35.9M).
C4 Therapeutics, Inc. Quarterly Revenue & Net Profit History
C4 Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $11.0M | +112.8% | $-20.5M | -186.0% |
| Q3 FY2025 | $11.2M | -26.9% | $-32.2M | -286.4% |
| Q2 FY2025 | $6.5M | -46.2% | $-26.0M | -402.6% |
| Q1 FY2025 | $7.2M | +138.2% | $-26.3M | -363.7% |
| Q4 FY2024 | $5.2M | +58.8% | $-34.6M | -667.8% |
| Q3 FY2024 | $15.4M | +38.7% | $-24.7M | -160.6% |
| Q2 FY2024 | $12.0M | +350.7% | $-17.7M | -147.6% |
| Q1 FY2024 | $3.0M | -19.2% | $-28.4M | -933.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $12.0M | $15.4M | $5.2M | $7.2M | $6.5M | $11.2M | $11.0M |
| YoY Growth | -19.2% | 350.7% | 38.7% | 58.8% | 138.2% | -46.2% | -26.9% | 112.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $398.4M | $381.1M | $376.1M | $349.6M | $319.5M | $296.5M | $265.5M | $359.1M |
| Liabilities | $140.1M | $134.0M | $133.4M | $133.6M | $124.4M | $122.5M | $111.1M | $102.5M |
| Equity | $258.3M | $247.1M | $242.7M | $216.0M | $195.1M | $174.1M | $154.4M | $256.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-18.1M | $-5.0M | $-24.1M | $-17.9M | $-33.3M | $-12.1M | $-31.2M | $-22.1M |